← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $611B	1,967	+136	+7%	$171B
2	2 Pfizer PFE $168B	1,737	+131	+8%	$138B
3	3 Merck MRK $359B	1,567	+97	+7%	$109B
4	4 AbbVie ABBV $501B	1,435	+138	+11%	$58B
5	5 Bristol-Myers Squibb BMY $124B	1,314	+126	+11%	$61.7B
6	6 Amgen AMGN $235B	1,155	+93	+9%	$70.1B
7	7 Gilead Sciences GILD $195B	1,100	+118	+12%	$124B
8	8 Novartis NVS $286B	816	+55	+7%	$20.5B
9	9 GSK GSK $98.3B	682	+47	+7%	$14.3B
10	10 Regeneron Pharmaceuticals REGN $82B	438	+24	+6%	$21B
11	11 AstraZeneca AZN $258B	380	+37	+11%	$8.01B
12	12 Jazz Pharmaceuticals JAZZ $13.9B	280	+31	+12%	$6.15B
13	13 Myriad Genetics MYGN $415M	271	+4	+1%	$2.21B
14	14 Incyte INCY $22.9B	231	+38	+20%	$8.12B
15	SGEN 15 DELISTED Seagen Inc. Common Stock SGEN	204	+6	+3%	$5.03B
16	16 Opko Health OPK $1.2B	156	+1	+0.6%	$599M
17	17 Geron GERN $790M	138	+33	+31%	$266M
18	18 DELISTED Immunogen Inc IMGN	135	-6	-4%	$1.11B
19	19 DELISTED Exact Sciences EXAS	131	+2	+2%	$756M
20	20 Exelixis EXEL $15.6B	131	+5	+4%	$1.44B
21	21 Halozyme HALO $13.8B	119	+9	+8%	$1.2B
22	22 Puma Biotechnology PBYI $543M	116	+24	+26%	$2.49B
23	SPPI 23 DELISTED Spectrum Pharmaceuticals Inc SPPI	115	-3	-3%	$378M
24	CLVS 24 DELISTED Clovis Oncology, Inc. CLVS	112	-4	-3%	$1.52B
25	25 DELISTED Assertio ASRT	104	+6	+6%	$422M